Want to see NAMS full AI Analyst Report?
Total Valuation
NewAmsterdam Pharma Company has a market cap or net worth of $3.96B. The enterprise value is $3.07B.
Market Cap$3.96B
Enterprise Value$3.07B
Share Statistics
NewAmsterdam Pharma Company has 116,903,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding116,903,980
Owned by Insiders6.26%
Owned by Institutions20.47%
Financial Efficiency
NewAmsterdam Pharma Company’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -33.01%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-33.01%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee225.03K
Profits Per Employee-2.04M
Employee Count100
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NewAmsterdam Pharma Company is ―. NewAmsterdam Pharma Company’s PEG ratio is 0.63.
PE Ratio―
PS Ratio178.34
PB Ratio5.87
Price to Fair Value5.87
Price to FCF-27.11
Price to Operating Cash Flow-29.22
PEG Ratio0.63
Income Statement
In the last 12 months, NewAmsterdam Pharma Company had revenue of 22.50M and earned -203.82M in profits. Earnings per share was -1.75.
Revenue22.50M
Gross Profit22.44M
Operating Income-225.68M
Pretax Income-203.82M
Net Income-203.82M
EBITDA-242.32M
Earnings Per Share (EPS)-1.75
Cash Flow
In the last 12 months, operating cash flow was -141.92M and capital expenditures -268.00K, giving a free cash flow of -142.19M billion.
Operating Cash Flow-141.92M
Free Cash Flow-142.19M
Free Cash Flow per Share-1.22
Dividends & Yields
NewAmsterdam Pharma Company pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.25
52-Week Price Change86.00%
50-Day Moving Average32.66
200-Day Moving Average33.51
Relative Strength Index (RSI)55.80
Average Volume (3m)1.54M
Important Dates
NewAmsterdam Pharma Company upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
NewAmsterdam Pharma Company as a current ratio of 7.88, with Debt / Equity ratio of <0.01%
Current Ratio7.88
Quick Ratio7.88
Debt to Market Cap<0.01
Net Debt to EBITDA2.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NewAmsterdam Pharma Company has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NewAmsterdam Pharma Company EV to EBITDA ratio is -14.54, with an EV/FCF ratio of -23.80.
EV to Sales156.57
EV to EBITDA-14.54
EV to Free Cash Flow-23.80
EV to Operating Cash Flow-23.84
Balance Sheet
NewAmsterdam Pharma Company has $636.11M in cash and marketable securities with $23.00K in debt, giving a net cash position of $636.08M billion.
Cash & Marketable Securities$636.11M
Total Debt$23.00K
Net Cash$636.08M
Net Cash Per Share$5.44
Tangible Book Value Per Share$5.97
Margins
Gross margin is 97.52%, with operating margin of -1002.90%, and net profit margin of -905.74%.
Gross Margin97.52%
Operating Margin-1002.90%
Pretax Margin-905.74%
Net Profit Margin-905.74%
EBITDA Margin-1076.86%
EBIT Margin-1077.83%
Analyst Forecast
The average price target for NewAmsterdam Pharma Company is $48.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$48.43
Price Target Upside39.64% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-52.13%
EPS Growth Forecast3.91%